Sirolimus is under clinical development by Biodexa Pharmaceuticals and currently in Phase II for Familial Adenomatous Polyposis. According to GlobalData, Phase II drugs for Familial Adenomatous Polyposis have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sirolimus’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sirolimus overview

Sirolimus (rapamycin) is under development for the treatment of acute respiratory distress syndrome (RAPA-CARDS) due to Coronavirus disease 2019 (COVID-19), non-muscle Invasive bladder cancer, prostate cancer and familial adenomatous polyposis. It is administered through oral route. The drug candidate is an encapsulated rapamycin consisting of sub-micron rapamycin particles incorporated into poly (methyl methacrylate) polymer. It was under development for the treatment of Alzheimer's disease and ageing.

Biodexa Pharmaceuticals overview

Biodexa Pharmaceuticals, formerly Midatech Pharma Plc, is a clinical-stage biopharmaceutical company. It develops a pipeline of products aimed at primary and metastatic cancers of the brain. The company’s pipeline products include MTX110, a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. and MTD217. Its product pipeline treats diffuse midline glioma, glioblastoma, medulloblastoma and leptomeningeal disease. The company conducts research and development programs in the areas of oncology, autoimmune diseases, octreotide and glioblastoma. Biodexa Pharmaceuticals is headquartered in Cardiff, Wales, the UK.

For a complete picture of Sirolimus’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.